CD19-Directed Monoclonal Antibodies

DBCAT005666Pharmacologic class

Monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities. A DrugBank category of 1 drug. 1 of them is approved.

Drugs: Loncastuximab tesirine

What you can answer from here — as of November 29, 2022

1DrugEach linked to its full drug card

Listed above

1Drug targetEvery drug–target pair in the class, with bond type

4Marketed productsAcross the regions we cover, with dosage forms and routes

1Route of administrationHow the drugs in this class are given

Which targets do CD19-Directed Monoclonal Antibodies share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account